Mar 04, 2022 8:30am EST Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
Mar 01, 2022 8:30am EST Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
Feb 17, 2022 8:30am EST Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Feb 14, 2022 8:30am EST Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Feb 09, 2022 6:30am EST Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
Feb 01, 2022 8:30am EST Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Jan 31, 2022 8:30am EST Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Jan 26, 2022 8:30am EST Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th
Jan 10, 2022 8:30am EST Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
Jan 03, 2022 8:30am EST Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022